---
title: "GENFIT to receive US$20M milestone from Ipsen as Iqirvo® surpasses US$200M in first year sales on PBC market."
description: "In Lille, France, Cambridge, Massachusetts, United States, and Zurich, Switzerland, on February 12, 2026, GENFIT (Euronext: GNFT), a biopharmaceutical company committed to enhancing the well-being of "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275791833.md"
published_at: "2026-02-12T17:37:44.000Z"
---

# GENFIT to receive US$20M milestone from Ipsen as Iqirvo® surpasses US$200M in first year sales on PBC market.

> In Lille, France, Cambridge, Massachusetts, United States, and Zurich, Switzerland, on February 12, 2026, GENFIT (Euronext: GNFT), a biopharmaceutical company committed to enhancing the well-being of patients with rare and severe liver ailments, revealed that the exceptional commercial success of Iqirvo® in its initial complete year on the primary biliary cholangitis (PBC) market has led to a significant US$20 million milestone payment from Ipsen as per their licensing deal.

In Lille, France, Cambridge, Massachusetts, United States, and Zurich, Switzerland, on February 12, 2026, GENFIT (Euronext: GNFT), a biopharmaceutical company committed to enhancing the well-being of patients with rare and severe liver ailments, revealed that the exceptional commercial success of Iqirvo® in its initial complete year on the primary biliary cholangitis (PBC) market has led to a significant US$20 million milestone payment from Ipsen as per their licensing deal.

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [GNFTY.US - GENFIT SPON ADS EACH REP 1 ORD SHS](https://longbridge.com/en/quote/GNFTY.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [GNFT.US - Genfit](https://longbridge.com/en/quote/GNFT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Madrigal 製藥因 Rezdiffra 的銷售，第四季度收入大幅增長 | Madrigal 製藥報告第四季度收入為 3.211 億美元，較去年大幅增長，儘管出現了淨虧損。該公司預計，由於疾病意識的提高，Rezdiffra 的銷售將實現強勁增長，並計劃與 FDA 就第二階段試驗設計進行諮詢。MASH 管道已通過新項 | [Link](https://longbridge.com/en/news/276330392.md) |
| BUZZ-Traws Pharma 在 FDA 將流感藥物申請置於臨牀擱置後股價下跌 | Traws Pharma 的股票在盤前交易中下跌了 20.81%，至 1.58 美元，此前美國 FDA 因對 tivoxavir marboxil 的突變性數據表示擔憂，將其新藥申請置於臨牀暫停狀態。該公司表示，此次暫停不會影響美國以外的正 | [Link](https://longbridge.com/en/news/276337113.md) |
| 艾伯維公司 SEC 10-K 年度報告 | 艾伯維公司發佈了其 2025 年 10-K 表格報告，展示了強勁的財務表現，淨收入為 611.6 億美元，比去年增長了 8.6%。主要亮點包括免疫學領域的增長、新產品發佈以及長期增長的戰略舉措。公司面臨的挑戰包括專利到期、監管壓力和供應鏈風 | [Link](https://longbridge.com/en/news/276480798.md) |
| 伊克力西斯董事 Jack L Wyszomierski 出售了 99,574 股股票 | 傑克·L·維索米爾斯基（Jack L Wyszomierski），Exelixis 的董事，於 2026 年 2 月 18 日出售了 99,574 股普通股，總金額為 4,382,251 美元，成交均價為每股 44.01 美元。出售後，他仍 | [Link](https://longbridge.com/en/news/276499134.md) |
| 解析 Ardelyx：7 位分析師分享他們的看法 | 在最新的季度中，7 位分析師對 Ardelyx（NASDAQ:ARDX）給出了混合評級，平均 12 個月目標價為 16.86 美元，比之前的目標上漲了 24.24%。主要分析師提高了他們的評級，其中 HC Wainwright、BTIG 和 | [Link](https://longbridge.com/en/news/276450068.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.